Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial

Liraglutide, a glucagon-like peptide-1 receptor agonist, has well known beneficial effects on glucose metabolism, and animal studies indicate that liraglutide also affects bone turnover by decreasing bone resorption. The primary objective of the study was to investigate the effect of liraglutide on...

Full description

Saved in:
Bibliographic Details
Published in:Bone (New York, N.Y.) N.Y.), 2020-03, Vol.132, p.115197-115197, Article 115197
Main Authors: Hygum, Katrine, Harsløf, Torben, Jørgensen, Niklas Rye, Rungby, Jørgen, Pedersen, Steen B., Langdahl, Bente L.
Format: Article
Language:English
Subjects:
Bone turnover
Diabetes
Gastrointestinal hormones
Liraglutide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liraglutide, a glucagon-like peptide-1 receptor agonist, has well known beneficial effects on glucose metabolism, and animal studies indicate that liraglutide also affects bone turnover by decreasing bone resorption. The primary objective of the study was to investigate the effect of liraglutide on bone turnover in patients with T2D. The study was a randomized, double-blinded, clinical trial. Sixty participants with T2D were randomized to treatment with liraglutide 1.8 mg daily or placebo for 26 weeks. The primary endpoint was change in p-collagen I cross-linked C-terminal telopeptide (p-CTX). P-CTX increased in patients treated with liraglutide by 0.07 (0.03; 0.10) μg/L (p 
ISSN:8756-3282
1873-2763
DOI:10.1016/j.bone.2019.115197